X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ALEMBIC PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ALEMBIC PHARMA BIOCON LTD/
ALEMBIC PHARMA
 
P/E (TTM) x 49.6 20.3 244.0% View Chart
P/BV x 7.2 4.8 150.8% View Chart
Dividend Yield % 0.2 0.7 22.6%  

Financials

 BIOCON LTD   ALEMBIC PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
ALEMBIC PHARMA
Mar-18
BIOCON LTD/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188645 184.2%   
Low Rs305470 64.9%   
Sales per share (Unadj.) Rs68.7166.1 41.4%  
Earnings per share (Unadj.) Rs7.621.9 34.5%  
Cash flow per share (Unadj.) Rs14.027.5 50.8%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.10.7 18.7%  
Book value per share (Unadj.) Rs86.3117.8 73.3%  
Shares outstanding (eoy) m600.00188.52 318.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.93.4 323.6%   
Avg P/E ratio x98.925.5 388.3%  
P/CF ratio (eoy) x53.420.3 263.5%  
Price / Book Value ratio x8.64.7 182.6%  
Dividend payout %13.218.3 72.5%   
Avg Mkt Cap Rs m447,900105,090 426.2%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3116,228 149.5%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,23431,308 131.7%  
Other income Rs m2,06270 2,933.1%   
Total revenues Rs m43,29631,378 138.0%   
Gross profit Rs m8,2916,431 128.9%  
Depreciation Rs m3,8511,055 365.2%   
Interest Rs m61534 1,808.8%   
Profit before tax Rs m5,8875,413 108.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,204 130.4%   
Profit after tax Rs m4,5314,128 109.8%  
Gross profit margin %20.120.5 97.9%  
Effective tax rate %26.722.2 119.9%   
Net profit margin %11.013.2 83.3%  
BALANCE SHEET DATA
Current assets Rs m41,48618,247 227.4%   
Current liabilities Rs m21,41311,235 190.6%   
Net working cap to sales %48.722.4 217.3%  
Current ratio x1.91.6 119.3%  
Inventory Days Days6486 74.7%  
Debtors Days Days9461 153.5%  
Net fixed assets Rs m50,66120,035 252.9%   
Share capital Rs m3,000377 795.8%   
"Free" reserves Rs m48,80821,824 223.6%   
Net worth Rs m51,80822,201 233.4%   
Long term debt Rs m17,8985,000 358.0%   
Total assets Rs m99,89739,411 253.5%  
Interest coverage x10.6160.2 6.6%   
Debt to equity ratio x0.30.2 153.4%  
Sales to assets ratio x0.40.8 52.0%   
Return on assets %5.210.6 48.8%  
Return on equity %8.718.6 47.0%  
Return on capital %9.619.7 48.8%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m12,05814,722 81.9%   
Fx outflow Rs m7,3487,026 104.6%   
Net fx Rs m4,7107,696 61.2%   
CASH FLOW
From Operations Rs m6,6213,124 211.9%  
From Investments Rs m-6,840-8,844 77.3%  
From Financial Activity Rs m-2,3975,026 -47.7%  
Net Cashflow Rs m-2,612-693 376.7%  

Share Holding

Indian Promoters % 40.4 74.1 54.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.9 289.7%  
FIIs % 10.7 9.1 117.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 13.9 143.2%  
Shareholders   109,995 49,328 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PLETHICO PHARMA  AJANTA PHARMA  UNICHEM LAB  NATCO PHARMA  ELDER PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Nov 16, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS